person

Mar G. C.

Country
Spain
Department
Allergologia

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
66
Sites with multiple studies

Has run more than one trial at 66 of 138 partner sites.

Specializations

Hereditary Angioedema Research

This investigator specializes in the therapeutic management of hereditary angioedema (HAE), focusing on both prophylactic treatments and acute attack management. Their research encompasses novel therapeutic approaches for Types I and II HAE.

  • Prophylactic Treatment Development
  • Acute Attack Management
  • Long-term Treatment Safety

The investigator evaluates various therapeutic compounds including deucrictibant, KVD900, and donidalorsen for HAE management.

Systemic Mastocytosis Studies

The investigator conducts research in systemic mastocytosis, with particular emphasis on indolent and smoldering variants. Their work involves evaluating novel therapeutic agents for symptom management and disease control.

  • Indolent Systemic Mastocytosis Treatment
  • Novel Therapeutic Approaches
  • Long-term Disease Management

Their research includes investigations of bezuclastinib, avapritinib, and elenestinib in treating various forms of mastocytosis.

Eosinophilic Conditions

The investigator studies eosinophilic esophagitis (EoE), examining innovative treatments for this chronic inflammatory condition. Their research focuses on addressing both histological and symptomatic aspects of the disease.

  • Inflammatory Response Management
  • Esophageal Dysfunction Treatment
  • Immunological Therapy Development

Their work includes evaluation of targeted therapies for improving esophageal function and reducing inflammation in EoE patients.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.